Infraredx to Present Results of the Lipid-Rich Plaque (LRP) Study at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 Scientific Symposium

Sept. 12, 2018 16:48 UTC

The highly anticipated study results will be presented at a late-breaking clinical trial session at TCT on Monday, September 24

BURLINGTON, Mass.--(BUSINESS WIRE)-- InfraReDx, Inc., a pioneer in intravascular imaging for mapping coronary artery disease, today announced that results from the highly anticipated Lipid-Rich Plaque (LRP) Study have been accepted as a late-breaking clinical trial at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, to be held on September 21 – 25, 2018 at the San Diego Convention Center.

The LRP Study a prospective, multicenter study is designed to identify a correlation between lipid core plaque (LCP) and the occurrence of major adverse cardiovascular events (MACE) within two years. At the time of index procedure, intravascular ultrasound (IVUS) plus near infrared spectroscopy (NIRS) technology was utilized, which can now be found on the Makoto™ Intravascular Imaging System and Dualpro™ IVUS+NIRS catheter, to assess vessel structure and plaque composition.

Recent studies have shown that LCP is an underlying cause of serious cardiac events. NIRS has demonstrated the capability to readily distinguish stable coronary plaque from potentially dangerous LCP compared to IVUS-alone. Combination IVUS+NIRS imaging offers cardiologists unparalleled insights into the role LCP plays in heart disease.

The LRP Study results will be presented in a late-breaking clinical trial session at the symposium.

TCT Late-Breaking Clinical Trials 4

  • Title: LRP: Assessment of Coronary Near-Infrared Spectroscopy Imaging to Detect Vulnerable Plaques and Vulnerable Patients
  • Date: Monday, September 24, 2018; 10:40-10:52 a.m. PDT
  • Location: San Diego Convention Center, Main Arena, Hall F, Ground Level

“The LRP Study was several years in the making and has the potential to change the field of interventional cardiology,” said Jason Bottiglieri, President and CEO of Infraredx. “We stand firm in our commitment to provide cardiologists with the most precise imaging tool required to predict and ultimately prevent heart attacks.”

Infraredx will also sponsor a satellite program, titled, “The New Frontier: Can We Finally Predict and Start Treating Vulnerable Plaque?” on Monday, September 24, 2018. The discussion will be moderated by the Principal Investigator of the LRP Study, Ron Waksman, MD, FACC of the MedStar Heart and Vascular Institute in Washington, D.C.

Presentation Theater Program

  • Title: The New Frontier: Can We Finally Predict and Start Treating Vulnerable Plaque?
  • Date: Monday, September 24, 2018; 11:30 a.m.-12:30 p.m. PDT
  • Location: San Diego Convention Center, Presentation Theater 5

About Infraredx, Inc.

Infraredx, Inc., a Nipro company, is advancing the diagnosis and management of coronary artery disease by providing cardiologists with the most precise imaging tools required to predict and ultimately prevent heart attacks. Its Makoto™ Intravascular Imaging System, with accompanying Dualpro™ IVUS+NIRS catheter, is the only technology on the market that is FDA-cleared for the detection of lipid core plaque (LCP). LCP, suspected to be vulnerable plaque, is well-documented in studies as the cause of most serious heart attacks. Infraredx is dedicated to advancing this important field of research and conducting landmark clinical trials to transform how we view and treat heart disease. For more information, please visit and connect with Infraredx on Twitter and LinkedIn.


Kaitlyn Dmyterko, 781-345-9634
JPA Health Communications
Lisa Rivero, 617-657-1305


Source: Infraredx, Inc.

Back to news